M/CLEAR
No clinical trial has been conducted to determine the efficacy of the antiparasitic drug ivermectin as opposed to coronavirus variants, according to Japanese drugmaker Kowa Co. , which said it would no longer seek approval of the drug as a treatment for COVID-19.
The Nagoya-based pharmaceutical and advertising company announced the effects of an international, randomized, double-blind clinical trial on Sept. 26. In the trial, 1030 patients with mild COVID-19 gained the drug orally for 3 days, then compared to others who won a placebo.
This is possibly due to a conflict with your security or ad-blocking software.
Upload japantimes. co. jp and piano. io to your list of sites.
If this doesn’t work or if you can’t load the domain names on your whitelist, stop by this help page.
We humbly for the inconvenience.
In an age of misinformation and too much information, quality journalism is more important than ever. By subscribing, you can help us tell the story well.
Your subscription plan allows you to comment. To be more informed, see our frequently asked questions
Japan Times Ltd. All rights reserved.